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Abstract
Background: Vitamin D (VD) may increase sirtuin 1 (SIRT1) and subsequently PPAR-γ coactivator 1α (PGC-1α) and
irisin levels and these improvements may reduce insulin resistance (IR). The aim was to assess the effects of vitamin
D supplementation on SIRT1, irisin, and IR in overweight/obese type 2 diabetes (T2D) patients.
Methods: Ninety T2D males and females were recruited as a clinical trial study (mean of age and body mass index
(BMI) of intervention and placebo groups were 50.05 ± 10.17 and 50.36 ± 10.2 yrs. and 31.37 ± 3.4 and 30.43 ±
3.2 kg/m2, respectively). The inclusion criteria were T2D, VD deficient, BMI > 25 kg/m2, and serum HbA1c < 8.5%.
The exclusion criteria were using vitamin and mineral supplements, having any acute disease, recent
modifying dose or type of drugs. The supplementation was 50,000 IU/week VD or placebo for 8 weeks. The
demographic characteristics, anthropometrics, dietary intakes and physical activity status, sun exposure status,
fasting blood sugar (FBS) and insulin, glycosylated hemoglobin (HbA1c), irisin, SIRT1, 25-hydroxy D3
(25(OH)VD), homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity
check index (QUICKI) were determined. The significant P-value was ≤0.05.
Results: The increase of serum VD, SIRT1, and irisin in the intervention group was significant (p < 0.001).
HbA1c was decreased significantly by 1%. The changes in the other glucose indices (FBS, insulin, and IR) were
non-significant.
Conclusions: VD supplementation may improve T2D by decreasing HbA1c and increasing SIRT1 and irisin in
VD deficient T2D patients. Further trials are suggested.
Trial registration: Iranian Registry of Clinical Trials, IRCT201604202365N11. Registered 21/08/2016, http://en.irct.
ir/trial/2019.
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Background
Diabetes mellitus is a metabolic disease characterized by
hyperglycemia resulting from defects in insulin secretion or
action or both [1]. Obesity is an important risk factor in-
creases cellular oxidative stress, insulin resistance (IR), and
pancreatic beta cells malfunction [2]. In addition, vitamin D
(VD) deficiency is highly prevalent in many societies and
ages. According to Iranian Multi-Centric Osteoporosis
Study (IMOS), 2009, 72.1% of men and 75.1% of women
had mild to severe VD deficiency. Globally, about 50% of
the population are VD deficient. It is estimated that about 1
billion people all over the world are affected by different
degrees of vitamin D deficiency [3–6].
According to recent studies, IR as the most important
cause of T2D was inversely related to VD [6–8]. Moreover,
serum 25-OH VD is significantly lower among diabetic
patients compared with non-diabetic ones [9, 10]. Also, the
relationship between serum 25-OH VD and insulin secre-
tion was significant according to some studies [11].
The hyperglycemia, hyperlipidemia, and inflammatory
cytokines in diabetes can likely increase oxidative stress
and decrease silent mating type information regulation 2
homolog 1 (sirtuin 1 [SIRT1]) levels [12].
Sirtuins as class III histone deacetylases are categorized
into 7 types among which, SIRT1 has been studied more
than other categories in humans. SIRT1 may play a role in
chronic diseases such as diabetes. It affects glucose metab-
olism in the liver, pancreas, muscle and adipose tissue.
The expression and activity of SIRT1 are reduced in hun-
ger, calorie restriction, and some chronic diseases such as
diabetes. Accordingly, SIRT1 activation may improve glu-
cose indices and mitochondria function [13–16].
In addition, VD may increase human endothelial
SIRT1 level and activity that can be downregulated by
Hydrogen Peroxide. Anti-cancer effects of VD are re-
lated to VD receptor (VDR) and Forkhead box O
(FOXO) protein interaction, phosphorylation stimula-
tion, and SIRT1. The insulin-sensitizing effect of VD is
likely in relation to SIRT1 [17].
Irisin is a myokine regulates energy metabolism in exercise
and improves insulin resistance [18]. It is secreted in
response to Peroxisome Proliferator-Activated Receptor
(PPAR)-γ Coactivator (PGC-1α), and low irisin levels may
decrease expression and activation of PGC-1α. Also, T2D
patients have low serum levels of irisin and PGC-1α [19–22].
According to the separate studies, VD may increase
SIRT1, and subsequently PGC-1α and Irisin. These
changes can improve insulin resistance. Thus, VD may
decrease insulin resistance by increasing SIRT1 and Iri-
sin (Fig. 1). So, this trial was planned to assess the effects
of vitamin D on serum glucose, SIRT1, and Irisin levels
in overweight/obese T2D patients.
Methods
Study design
This double-blinded randomized clinical trial was con-
ducted on 90 obese T2D patients at Shahid Beheshti
Diabetes Clinic, Bandar-E-Anzali, Gilan, Iran. The study
lasted from the beginning of autumn 2016 to the end of
autumn 2016.
Fig. 1 A schematic for the relationship of vitamin D (VD), sirtuin1 (SIRT1), PPAR-gamma coactivator 1-alpha (PGC-1α), insulin resistance (IR), Irisin,
and diabetes. (UCP1: Uncoupling Protein 1; FGF21: Fibroblast Growth Factor 21; PPAR-γ: Peroxisome Proliferation Activated Receptor-Gamma; IL-6:
Interleukin 6; TNF-α: Tumour Necrosis Factor-Alpha; hs-CRP: high-sensitivity C-Reactive Protein; NF-κB: Nuclear Factor kappa-light-chain-enhancer
of activated B cells)
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The participants signed a “written informed consent
form” at the beginning. Ninety patients were randomly
divided into placebo or intervention groups with a 1:1
ratio. The intervention group took 8 VD pearls (50,000
IU/week, Zahravi Co®), and the placebo group took simi-
lar pearls containing oral paraffin without VD (50,000
IU/week, Zahravi Co®). The duration of the intervention
was 8 weeks. During the intervention, the compliance
status including follow-up, side effects, and complica-
tions was weekly checked by calling. At the end, the
number of the used pearls, returned blisters, and packs
were recorded.
Inclusion criteria were 25–65 years old, having
T2D, serum HbA1c < 8.5%, 25 kg/m2 ≤ BMI, and the
written informed consent form. Exclusion criteria
were the inability to cooperating, acute diseases influ-
encing the intervention, intake of the antioxidant and
multivitamin-mineral supplements during the past 3-
months so far, changing the type and dose of T2D
medications, and taking less than about 90% of the
study’s supplements.
The outcomes were serum 25-OH VD, SIRT1, Irisin,
HbA1c, IR indexes, FBS, and serum insulin.
Measures
At the beginning and end, the demographic character-
istics, anthropometrics, and dietary intakes by two 24-
h food recall (a weekend and a working day) were
determined. Physical activity was measured by a short
form of the international physical activity question-
naire (IPAQ) [23]. The sun exposure status was
assessed using a valid questionnaire [24]. At the
beginning and end, the blood taking from the brachial
vein for measuring the serum factors was done.
Serum glucose was measured by the Olympus® device
and Delta® kits.
The glycosylated hemoglobin was determined using
Nycocard® kits in Nyco Card Reader® (Made in
Norway). Insulin was measured by the Cobas e 411®
device and Roche® kit. Irisin was measured by Zellbio
GmbH kit Cat.No: ZB-13253 J-H9648 (Germany)®, with
a normal range of 2–80 ng/ml and sensitivity of 0.1
ng/ml. SIRT1 was measured by Zellbio GmbH kit
Cat.No: ZB-12557 J-H9648(Germany)®, with a normal
range of 5–160 ng/ml and sensitivity of 1 ng/ml.
ELISA method; ELISA reader (Model: Tecan A-5082
Made in Austria®).
25-OH VD was measured by 25-(OH) D3 quantita-
tive diagnostic kit (Immuno Diagnostic Systems (IDS),
UK)®, which is an Enzyme Immunoassay kit with a
sensitivity of 5 nmol/L. The ELISA method and ELISA
reader (Model: Tecan A-5082 Made in Austria®) were
used for Irisin, SIRT1, and 25-OH D3. The insulin
resistance was determined by HOMA-IR and QUICKI
indexes [25, 26] as the following formula:
Insulin resistance ¼ ½fasting glucose mmol=Lð Þ
fasting insulin μIU=mlð Þ=22:5
Insulin Sensitivity ¼ 1 ½ log fasting glucose mmol=lð Þ
þ log fasting insulin μIU=mlð Þ
Statistical analysis
According to the Baziar et al study with 1.33 mean dif-
ference of HOMA-IR, 1.18 standard deviation for vita-
min D group, and 2.84 standard deviations for placebo
group [27], the sample size was calculated 45 peoples in
any groups using G-Power software and considering α =
5%, β = 20%, and dropout percentage = 12.5%.
Randomization was done using 23 quadratic blocks
and www.sealedenvelope.com. The blinding was accord-
ing to unique codes produced by software for each sub-
ject. Non-parametric, t-test, Mann-Whitney, Chi-square,
and ANCOVA tests and SPSS16 statistical software were
used for the analyses. The final analysis model was ad-
justed for the baseline values as potential confounders.
P-value < 0.05 was statistically considered significant.
The dietary intakes were analyzed by the Nutritionist(IV)
software. The modified intention-to-treat (m-ITT)
method [28] was used for the missing data (3 partici-
pants in the intervention group and 2 ones in the pla-
cebo group) (Fig. 2).
This clinical trial was approved by the ethics committee
of Iran University of Medical Sciences (IUMS) (Code:
IR.IUMS.REC.1395.9223475201), and Iranian Registry of
Clinical Trials (IRCT) (Registration No: IRCT2016042023
65N11). An informed consent form (in Persian) obtained
from all the participants. Participation was free, and a par-
ticipant could withdraw at whatever point the person feels
he/she was unable to continue. The dose of VD was for in-
sufficient VD status that side-effects had not been reported
previously [29]. All of the ethical codes were according to
the Helsinki agreement [30]. The personal information of
participants was kept secret before, during, and after the
trial. After measurements, at the end, a VD supplement
was given to the placebo group according to the protocol.
Results
According to the flow diagram of participants, a total of
176 T2D patients referred to the diabetes clinic were
screened (informed consent, medical history, question-
naire), of whom 86 patients did not meet the eligibility cri-
teria. Ninety participants were randomized that 5 patients
did not complete the study (for personal reasons; VD group
n = 3; placebo n = 2). Thus 85 participants completed the
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trial (VD group n = 42; placebo n = 43) and the data of
them were analyzed (Fig. 2).
Most of the participants were women with type 1
obesity (30 ≤ BMI < 35 [BMI = 34.25 kg/m2, weight: 59–
115 kg, height: 163–184.5 cm]), the mean age of 50 years
(25–65 year), recent diagnosed T2D nearly less than 6
years, and consumption of maximum 2 types of anti-
hyperglycemic medications. The baseline characteristics
including age, gender, weight, height, BMI, duration of
diabetes, type and dose of medications, and employment
status were similar between two groups before interven-
tion (Table 1).
Physical activity status (MET-min/week) was not sig-
nificantly different between the two groups. Within the
placebo group, weight and BMI decreased significantly
(P < 0.05). However, these differences were not signifi-
cant between the two groups (P > 0.05) (Table 2).
Energy, macronutrients, micronutrients, and antioxi-
dant intakes were not significantly different within and
between groups (Tables 3 and 4). Within the VD group,
zinc intake increased significantly (P < 0.05), but within
the placebo group, zinc intake decreased significantly
(P < 0.05). However, this difference was not significant
between the two groups (P > 0.05, Table 4).
Fig. 2 Flow diagram of participants with type 2 diabetes and overweight/obesity grade 1
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According to the final analysis model, the differences
of serum VD, SIRT1, Irisin, and HbA1c were significant
within and between groups (P < 0.05). Serum VD level
was doubled compared to the baseline level, and HbA1c
decreased by 1% among the VD group (Table 5). Within
the VD group, irisin and SIRT1 increased significantly
(P < 0.05). The differences in fasting glucose and insulin,
HOMA-IR, and QUICKI were not significant between
the two groups (Table 6). The sun-exposure status was
not significantly different within and between groups.
Safety
The patients reported no side effects associated with
treatment.
Discussion
Vitamin D supplementation (50,000 IU/week) for 8 weeks
increased serum VD levels in T2D patients with VD defi-
ciency. Compared to placebo, VD increased SIRT1 and
Irisin and decreased HbA1c by 1% significantly. The
differences in fasting insulin and glucose, HOMA-IR, and
QUICKI were not significant. Within the placebo group,
serum VD levels decreased significantly.
The results of some studies of the effects of VD sup-
plementation on diabetes showed controversy that the
following is referred to some of them.
In some studies, VD effects on insulin and glucose levels
of diabetic patients were similar to our trial [31–36].
In line with our results, Polidoro et al, 2013 reported
that SIRT1 and Irisin levels increased in the VD group
and decreased in the placebo group significantly [17].
The decreases can likely be attributed to progressing VD
deficiency in the placebo group after 2 months.
In Anastasilakis et al, 2013 study, irisin levels after
osteoporotic fractures in postmenopausal women with
low bone mineral density for 3 months didn’t show a sig-
nificant correlation with serum 25(OH)VD levels. The
decrease of Irisin was related to physical inactivity and a
sedentary lifestyle during fracture [37]. In another study
on healthy peoples, a one-time injection of 100,000 IU
Table 1 The mean and standard deviation of the baseline characteristics of type 2 diabetes patients





Age (Y) – 50.36 (10.2) 50.05 (10.7) 0.892*
Weight (kg) – 77.38 (10.9) 79.27 (11.6) 0.442*
Height (cm) – 159.35 (8.0) 158.77 (7.6) 0.736*
BMI (kg/m 2)) – 30.43 (3.2) 31.37 (3.4) 0.194*
Disease duration (months) – 65.52 (38.5) 67.02 (35.4) 0.664*
Medications (per day) Metformin (500 mg/d) 2.11 (1.13) 2.51 (1.26) 0.135*
Glibenclamide (5 mg/d) 1.31 (0.94) 0.95 (0.78)
Gender Male 7.00 (16.7) 8.00 (18.6) 0.815**
Female 35.00 (83.3) 35.00 (81.4)
Employment status Unemployed 32.00 (76.2) 32.00 (74.4) 0.850**
employed 10.00 (23.8) 11.00 (25.6)
*Independent t-test; **Chi-square test, Y Year, kg Kilogram, cm Centimeter, BMI Body mass index, mg Milligram






Physical activity (MET. Minutes/week) Baseline 685.50 (99–34,755) 462.00 (99–28,560) 0.346
After intervention 693.00 (99–33,831) 462.00 (99–28,659) 0.333
P-value** 0.104 0.811
Weight (kg) Baseline 77.38 (10.92) 79.27 (11.67) 0.442
After intervention 77.13 (10.81) 78.77 (11.53) 0.502
P-value** 0.076 0.011
BMI (kg/m2) Baseline 30.43 (3.23) 31.37 (3.40) 0.194
After intervention 30.34 (3.32) 31.18 (3.42) 0.254
P-value** 0.097 0.009
*Independent t-test, **Paired t-test, kg Kilogram, cm Centimeter, BMI Body mass index, mg Milligram, MET Metabolic equivalent
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VD increased serum 25(OH)VD levels and the changes
of serum irisin were non-significant. Only in one subject
out of 28, the serum irisin increased by three times;
which may be related to genetic variations in response
to the intervention [38].
A study in 2017 showed serum irisin levels were
decreased after 2 weeks’ mountain climbing. The possible
reasons were exposure to hypoxia, the energy-related
mechanisms, and the revitalization of musculoskeletal cells
in response to hypoxia [39].
The changes in physical activity in our study were not
significant. Accordingly, the improvement of serum iri-
sin levels in the VD group was independent of physical
activity levels. On the other hand, the decrease and in-
crease of irisin can be related to serum VD levels or the
dietary intake of VD in T2D patients.
According to the different studies, the effects of VD
on glucose indices are controversial.
Similar to our study, two separate studies with 50,000
IU/d VD didn’t find significant effects on FBS levels [33,
Table 3 The mean and standard deviation of energy intake, macronutrients, and micronutrients before and after intervention in






Energy (kcal/day) Baseline 1638.59 (377.82) 1578.38 (399.64) 0.478
After intervention 1701.36 (485.61) 1564.68 (392.75) 0.157
P-value** 0.381 0.871
Protein (g/day) Baseline 82.27 (23.34) 78.79 (31.82) 0.568
After intervention 89.31 (35.83) 80.31 (32.16) 0.226
P-value** 0.190 0.823
Carbohydrate (g/day) Baseline 232.69 (67.62) 220.85 (54.71) 0.377
After intervention 231.41 (62.34) 214.21 (51.19) 0.168
P-value** 0.891 0.522
Total fat (g/day) Baseline 47.61 (11.25) 46.83 (12.22) 0.760
After intervention 51.31 (17.33) 47.41 (14.13) 0.258
P-value** 0.199 0.830
SFA (g/day) Baseline 16.10 (4.58) 15.35 (3.75) 0.413
After intervention 16.01 (6.10) 15.74 (4.54) 0.819
P-value** 0.913 0.639
MUFA (g/day) Baseline 16.06 (3.85) 15.59 (5.07) 0.636
After intervention 17.13 (5.85) 15.56 (4.86) 0.182
P-value** 0.265 0.976
PUFA (g/day) Baseline 9.98 (3.04) 10.04 (3.45) 0.836
After intervention 10.49 (2.47) 9.97 (3.86) 0.480
P-value** 0.365 0.919
Calcium (mg/day) Baseline 835.33 (279.75) 838.41 (301.51) 0.961
After intervention 804.44 (324.89) 833.63 (292.95) 0.665
P-value** 0.487 0.929
Phosphorus (mg/day) Baseline 1444.29 (402.18) 1364.80 (372.84) 0.347
After intervention 1459.15 (467.88) 1355.23 (388.99) 0.268
P-value** 0.814 0.897
Vitamin D (μg/day) Baseline 1.73 (1.28) 1.84 (1.41) 0.710
After intervention 1.58 (1.18) 1.64 (1.22) 0.835
P-value** 0.386 0.334
Total fiber (g/day) Baseline 29.23 (10.67) 26.58 (7.56) 0.192
After intervention 29.96 (8.25) 25.91 (9.05) 0.578
P-value** 0.127 0.603
*Independent t-test, **Paired t-test, SFA Saturated fatty acid, MUFA Mono unsaturated fatty acid, PUFA Poly unsaturated fatty acid
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34]. However, in two other studies, the increased serum
VD levels were significantly related to FBS [40, 41]. The
likely reasons may be the dietary patterns, timing or type
of hyperglycemia medications, and the genetic differ-
ences of the populations.
In contrast, some studies of VD effects reported a sig-
nificant improvement in fasting serum insulin [34, 42–44].
The potential mechanisms may be the presence of VD
receptors (VDRs) in pancreas cells and expression of 1-
alpha-hydroxylase in them [37] and the existence of some
elements on human insulin promotors that respond to
VD and can activate insulin gene transcription [38–40].
In line with this trial, the different studies showed a
significant decrease in HbA1c of diabetics’ patients [33,
34, 43, 44]. However, the effect of VD on HbA1c was
non-significant in two separate studies [45, 46]. The rea-
sons may be the unadjusted potential confounders and
the different design of these studies. The potential mech-
anisms are unknown.
No significant changes in insulin resistance and sensitiv-
ity of our trial were similar to Jorde et al, 2010 study [40],
and SUNNY trial [34]. However, some studies reported a
significant improvement in HOMA-IR or QUICKI with
vitamin D [43, 44, 47]. The reason may be changing fast-
ing serum glucose and insulin levels after the intervention.
Vitamin D may decrease blood glucose by increasing insu-
lin sensitivity, glucose uptake of peripheral tissues, and
glycogen synthesis in liver [14]. The existence of VDR and
expression of 1-α-hydroxylase in pancreatic cells may be a
probable mechanism of the VD effect on insulin secretion
[48]. Also, response elements to VD in human insulin pro-
moters may activate insulin gene transcription [15, 16].
The lower serum 25(OH)-VD level is associated with
abdominal and peripheral obesity, physical inactivity,






Beta-Carotene (micg/day) Baseline 3780.76 3117.63 5440.75 6623.31 0.242
After intervention 4379.33 4073.18 4419.51 4235.22
P-value** 0.362 0.963
Vitamin A (micg/day) Baseline 878.74 663.17 893.10 723.97 0.952
After intervention 757.20 433.10 781.86 489.78
P-value** 0.059 0.947
Vitamin E (mg/day) Baseline 15.79 4.15 15.96 4.63 0.951
After intervention 15.42 4.18 15.67 4.13
P-value** 0.882 0.522
Vitamin C (mg/day) Baseline 122.87 81.12 139.18 108.88 0.596
After intervention 120.19 74.06 123.56 76.57
P-value** 0.101 0.528
Selenium (mg/day) Baseline 238.09 54.43 235.76 88.75 0.386
After intervention 213.06 61.64 230.75 83.54
P-value** 0.696 0.887
Zinc (mg/day) Baseline 20.61 5.82 20.46 5.85 0.306
After intervention 20.96 6.40 19.39 6.05
P-value** 0.003 0.005
Manganese (mg/day) Baseline 12.57 3.61 12.83 5.54 0.381
After intervention 11.48 4.04 12.79 4.62
P-value** 0.240 0.052
Copper (micg/day) Baseline 2.79 0.75 2.67 1.05 0.268
After intervention 2.54 0.75 2.73 0.93
P-value** 0.364 0.988
Magnesium (mg/day) Baseline 717.30 168.48 725.50 247.19 0.461
After intervention 680.08 191.00 732.94 224.49
P-value** 0.695 0.284
*Independent t-test, **Paired t-test
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smoking, alcohol intake history, and the lower dietary
intake of fish. In addition, obesity and physical inactiv-
ity are important risk factors for T2D. However, in this
trial, differences in physical activity levels were non-
significant. Serum VD levels can be directly related to
central adiposity [49] wasn’t measured in our partici-
pants. Accordingly, the relationship between Vitamin D
and glucose profiles can also be interpreted.
Vitamin D can increase insulin receptor gene expression
in beta cells, glucose transport in the intestine [50], and
intestinal calcium absorption may serve as stimuli for
insulin release. In addition, some VDRs on beta cells can
turn 25(OH)D3 (calcidiol) into the active VD [51, 52].
The more reasons for the differences between our trial
and other studies may be unadjusted confounders, the
different designs, the variety of dietary patterns, and the
dose or timing of hyperglycemia medications.
This study has several strengths. First, the double-
blinded stratified blocked randomization design; Second,
considering multiple eligibility criteria; Third, the deter-
mining of dietary intakes and physical activity status and
adjusting the statistical analysis for them and other po-
tential confounders; Fourth, considering control group.
These strengths are likely preferable in comparison with
the few other clinical trials that have evaluated the ef-
fects of VD in T2D.
However, our study had some limitations. First, the
sample size was small; Second, the intervention duration
was likely short to understand the real effects of VD sup-
plementation on the different markers in T2D patients;





crude P-value* Adjusted P-value***
VitaminD (ng/ml) Baseline 17.24 (7.83) 17.56 (7.82) 0.853 < 0.001
After intervention 38.86 (10.76) 14.79 (7.08) < 0.001
P-value** < 0.001 < 0.001
HbA1c (%) Baseline 7.51 (0.87) 7.15 (1.12) 0.103 < 0.001
After intervention 6.76 (0.98) 7.21 (1.11) 0.051
P-value** < 0.001 0.657
SIRT1 (ng/ml) Baseline 24.94 (4.38) 25.57 (3.37) 0.455 < 0.001
After intervention 27.90 (5.58) 23.40 (3.88) < 0.001
P-value** < 0.001 < 0.001
Irisin (ng/ml) Baseline 18.15 (5.96) 20.13 (7.17) 0.171
After intervention 21.99 (5.93) 14.98 (2.76) < 0.001 < 0.001
P-value** < 0.001 < 0.001
HOMA-IR (N) Baseline 5.36 (3.23) 5.83 (3.09) 0.499 0.421
After intervention 6.44 (3.73) 7.39 (4.58) 0.295
P-value** 0.006 0.003
QUICKI (N) Baseline 0.76 (0.08) 0.73 (0.06) 0.149 0.645
After intervention 0.73 (0.07) 0.71 (0.07) 0.217
P-value** 0.005 0.003
*Independent t-test, **Paired t-test, ***ANCOVA






FBS (mg/dl) Baseline 172.48 (62.16) 178.28 (71.74) 0.629 0.130
After intervention 175.52 (65.44) 162.72 (61.36) 0.355
P-value** 0.742 0.053
Insulin (micIU/ml) Baseline 12.64 (5.94) 14.09 (6.43) 0.284 0.101
After intervention 15.31 (7.24) 18.77 (9.02) 0.055
P-value** 0.002 < 0.001
*Independent t-test, **Paired t-test, ***ANCOVA
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Third, disregarding non-obese patients. Fourth, self-
reporting of diet and physical activity; Fifth, failure to
measuring serum parathyroid hormone (PTH), Apo-
lipoprotein A1, and the more sensitive inflammatory fac-
tors; Sixth, 24-h food recall is not a good index for asses-
sing the usual food intake; Seventh, failure to measuring
body composition. Even so, this study is the first trial of
VD effects on serum SIRT1 and irisin levels in over-
weight/obese T2D patients.
We suggest similar trials measuring adipose tissue dis-
tribution and considering more potential confounders
and the longer intervention period.
Conclusion
Vitamin D supplementation improves serum 25-(OH)
VD, SIRT1, irisin, and glycosylated hemoglobin in VD
deficient T2D patients. The decrease of HbA1c may be
related to the increased serum VD and irisin levels. Fur-
ther trials are suggested.
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